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ABSTRACT
Background: Tobacco smoking leads to death or disability and a drain on national resources. The
literature suggests that cigarette smoking continues to be a major modifiable risk factor for a variety of
diseases and that smokers aged 18 – 30 years are relatively resistant to anti-smoking messages due
to their widely held belief that they will not be lifelong smokers.

Objective: To conduct a randomised controlled trial (RCT) of a computer-generated ageing
intervention to promote smoking cessation among young adult smokers within a community pharmacy
setting.

Methods: A trial was designed with 80% power based on the effect size observed in a published pilot
study, 160 subjects were recruited (80 allocated to the control group and 80 to the intervention group)
from eight metropolitan community pharmacies geographically around Perth city centre, Western
Australia.

All participants received standardised smoking cessation advice. Intervention group

participants were also digitally ‘photo-aged’ by the researcher using internet based APRIL® Face
Aging Software so they could preview images of themselves as a lifelong smoker and a non-smoker.
Due to the nature of the intervention the participants and researcher could not be blinded to the study.
The main outcome measure was quit attempts at six-month follow-up, both self-reported and
biochemically carbon monoxide (CO) validated, and nicotine dependence assessed via the
Fagerström scale.

Results: At six-month follow-up, five out of 80 control group participants (6.3%) suggested they had
quit smoking but only one out of 80 control group participants (1.3%) consented and was confirmed
by carbon monoxide validation. In the intervention group, 22 out of 80 participants (27.5%) reported
quitting, with 11 out of 80 participants (13.8%) confirmed by CO testing. This difference in
biochemically confirmed quit attempts was highly significant (P = .003, Chi-square test). A repeated
measures analysis suggested the average intervention group smoking dependence score had also
significantly dropped compared to control participants (P <.001). These differences remained highly
significant after adjustment for small differences in gender distribution and nicotine dependence
between the groups. The mean cost of implementing the intervention was estimated at AUD 5.79 per
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participant. The incremental cost-effectiveness ratio was AUD 46 per additional quitter. The mean
cost which participants indicated they were willing to pay for the digital ageing service was AUD 20.25
(SD=15.32).

Conclusion: Demonstrating the detrimental effects on facial physical appearance using a computergenerated simulation may be both effective and cost-effective at persuading young adult smokers to
quit.

Trial ID Number: Australian New Zealand Clinical Trials Registry ACTRN12609000885291
http://www.anzctr.org.au/

Keywords: Tobacco smoking; nicotine dependence; physical appearance intervention.
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Internet based age progression simulation to promote smoking cessation facilitated
in pharmacies in Australian primary care: A randomised controlled trial
INTRODUCTION
Tobacco smoking leads to premature death or morbidity and places a drain on national resources.
Consequently, health professionals and governments stress the importance of smoking cessation and
reduction in exposure to tobacco smoking [1,2].
The younger people are when they start smoking, the greater the risk of illness or death caused by
smoking [3]. Approximately half of smokers die prematurely from their habit, with half of these in
middle age [4]. Smoking reduces life expectancy by approximately seven years, with significant
morbidity in the final years of a shortened life [4,5]. Even those who consume between one and four
cigarettes per day triple their long-term risk of dying from cardiovascular disease or lung cancer [6].
Currently in Australia, 19.7% of males and 16.3% of females aged 20–29 years smoke on a daily
basis [7]. The detrimental long-term health effects of smoking, such as cardiovascular diseases and
a variety of cancers are generally well-known in Australia [8]. However, health promotion research
shows that, in isolation, knowledge about the hazards of smoking is insufficient to deter smoking
behaviours [9]. Young adults who smoke are generally not concerned about the long-term health
consequences of smoking because they may believe they will give up the habit while still young [10].
A number of previous studies have investigated the potential of personalised, computer-generated,
facial ageing software to prompt quit attempts in young adult smokers. These have generally found
facial ageing interventions to have some impact [11-14].
The objectives of this randomised controlled trial were to test the efficacy and cost-effectiveness of an
intervention based on personalised, vivid illustrations of ‘smoker’s face’ amongst young smokers (18–
30 years of age). Efficacy was assessed by comparing: successful quitting, number of quit attempts
and change in smoking dependence (assessed by the Fagerström score), between the intervention
and control groups. The study also aimed to explore the value (feasibility and cost) of an unfunded
intervention within pharmacy practice.
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METHODS
Study design and population:
This study was a randomised controlled trial (RCT) [Trial ID number: ACTRN12609000885291]
recruiting 160 participants (80 participants assigned equally to both control and intervention groups)
from eight metropolitan community pharmacies geographically around Perth city centre, Western
Australia, when presenting to collect prescribed medications or over the counter (OTC) medications.
Eligibility criteria included:
i)

age range of 18–30 years old (self-report);

ii)

smokers (defined as smoking one or more cigarettes per day - self-report);

iii)

able to give consent;

iv)

available for follow-up at six months;

v)

no beards, moustaches or non-removable facial accessories;

vi)

no body dysmorphia;
[participants screened using the Body Dysmorphic Disorder Questionnaire (BDDQ)] [15]

vii)

not using nicotine replacement therapy (NRT) or taking oral drugs for nicotine
dependence.

Sample size and strategy:
The sample size of 80 participants per group was calculated to observe a medium effect size (d=0.5),
with 80% power and a type I error probability of 5%, and allowing for a 50% attrition rate. The
anticipated effect size and attrition rates were based upon the results of a pilot study [16]. At each
pharmacy participants were recruited and assigned by the researcher to the different arms of the
study on alternate weeks to minimise contamination between intervention and control participants.
The study aimed to recruit 10 participants from each of the eight pharmacies to each treatment arm
(intervention or control). This stratification by pharmacy was performed in an attempt to avoid any
bias due to socioeconomic factors.

The intervention:
April® Face Aging Software is an internet based 3D age progression software package which creates
a stream of aged images of faces from a standard digital photograph (the wrinkling/ageing algorithms
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based upon normative data from people of a broad variety of ages, ethnicities, lifestyle habits, as well
as published data regarding facial changes associated with ageing). Additionally, the resulting aged
images can be adjusted to compare how a person will age as a smoker versus a non-smoker (Figure
1 and 2).

Data collection:
At recruitment all participants were asked to complete a baseline questionnaire consisting of
demographic data, the Fagerström Smoking Dependence Scale [score from 0–10] [17], questions
concerning attitudes towards personal appearance, opinions about health risks associated with
smoking, and perceived barriers to quitting smoking. Participants were only recruited if they were
neither using NRT nor taking oral drugs for nicotine dependence. Participants in both the intervention
and control groups received standard two minute smoking cessation advice from the pharmacist.
Participants in the intervention group were also screened for body dysmorphia using the BDDQ. In
addition, they were photographed and their images digitally aged as a smoker and non-smoker (using
the internet based April® Face Aging software), and invited to view the age-processed images (Figure
3). They were also asked to complete a questionnaire about their willingness to pay (WTP) for the
digital ageing service. The digitally-aged photograph was then sent to their nominated email address
within 24 hours of the intervention. Follow-up surveys were undertaken via telephone at one, three
and six months and took approximately three minutes to complete.

At the six-month follow-up, if participants stated that they had quit smoking, they were reviewed within
48 hours to undertake a carbon monoxide (CO) breath test to validate their non-smoking status. The
CO monitor utilised was a Pico+Smokerlyzer® (portable and battery operated; manufactured by
Bedfont Scientific Ltd, Kent, England) and it provided a CO level reading in ppm (parts per million).

Primary outcomes measured:
i)

the effect of the intervention using successful quitting, quit attempts, progression along
the transtheoretical “stages of change” model;

ii)

nicotine dependence using the Fagerström scale.

These were measured at the following stages: baseline, one, three and six months follow-up.
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The demographic and baseline smoking habit profiles of the recruited subjects were compared
between groups using Fisher’s exact test and Pearson’s chi-square test for categorical variables, and
Student’s t-test for continuous variables. The primary endpoints of the study at the six-month followup were analysed using chi-square tests to compare percentages of quitters in each group, or t-tests
to compare smoking dependence levels. Percentages of quitters in each group were compared both
as ‘self-reported’ values and as ‘CO-validated’ values. A logistic regression model was used to
analyse the percentage of quitters in the two groups after adjustment for any possible differences
between groups on the basis of demographic or baseline data. A repeated measures analysis
(random effects regression model) was used to identify any changes in the Fagerström dependence
score over the entire course of the study, using one- and three-month follow-up surveys in addition to
baseline and six-month data. Data were analysed using SAS v9.2 software with P<.05 taken to
indicate a statistically significant association.

Secondary outcomes measured:
i)

the cost-effectiveness of the intervention from a health sector perspective in terms of the
incremental cost per additional quitter and per additional lifetime quitter;

ii)

the business viability of delivering the intervention in a community pharmacy.

These were calculated at the conclusion of the study.

Two perspectives were adopted: a health sector perspective and the perspective of a community
pharmacy on the assumption that the intervention was not government funded. The direct costs of
providing the digital ageing service over and above providing standard cessation advice were
calculated based on the time taken to provide the service and the cost to a pharmacy of purchasing
tokens to use online software to ‘photo-age’ participants. The cost of a pharmacist’s time was valued
based on award rates of pay in Western Australia [18] and tokens were costed based on market price
[19]. Time taken that was protocol driven was excluded. Potential cost offsets from a reduction in
health care costs of quitters were used to calculate net intervention costs. Cost offsets were based on
the Quit Benefits Model, which is a tool developed in Australia to predict the difference in health care
costs of smokers and non-smokers for males and females by age group after 10 years follow-up [20].
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This follow-up period was considered long enough to show the beneficial impact of quitting but short
enough to remain within the time frame of policy-makers. Cost offsets were discounted at a rate of 3%
as recommended by the US Panel on Cost-Effectiveness in Health and Medicine [21]. All costs were
expressed in 2011 Australian dollars. The cost of the tokens was converted from United States
dollars to Australian dollars based on the average exchange rate in 2011 [22]. The number of lifetime
quitters was calculated assuming a long-term smoking relapse rate of 37% within 10 years [23].
Smoking relapse after 10 years of abstinence has been found to be less than 1% per year [24].
To assess the robustness of the study results, a scenario sensitivity analysis with the ‘best-case’ and
‘worst-case’ scenario was performed [25]. The parameters varied were the pharmacist’s time spent
providing the service, the exchange rate for converting the cost of tokens from US dollars to
Australian dollars and the discount rate (Table 1).

Table 1. Parameter values: base case and sensitivity analysis
Item
Pharmacist time per participant to deliver service (mins)
Award wage rate per week for a pharmacist (AUD)
Cost of a token (AUD)
Exchange rate
Discount rate (%)

Base case
4.8
907.40
3.87
USD 1 = AUD
0.9687
3

Scenario sensitivity analysis
‘Best-case’
‘Worst-case’
3.6
6.0
3.63
6.53
USD 1= AUD
USD 1 = AUD
0.9067
1.6321
0
5

In the ‘best-case’ scenario the pharmacist’s time was adjusted down by 25%, the exchange rate for
converting US dollars to Australian dollars was varied to the lowest in the past five years, and a
discount rate of 0% was used [22]. In the ‘worst-case’ scenario the pharmacist’s time was adjusted up
by 25%, the exchange rate was varied to the highest in the past five years, and a discount rate of 5%
was used. The quantitative data from the customer survey (WTP questionnaire) were analysed using
SPSS v17 software. Customers’ perceptions about the value of the intervention and its impact on
loyalty intentions and potential future sales were analysed using simple descriptive statistics.
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RESULTS
Study design and population:
Customers were screened for eligibility to the RCT from eight community pharmacies (Figure 4):

Figure 4: Profile of the randomised controlled trial (using CONSORT guideline)

Enrolment

Assessed for eligibility (n=1259)

Excluded (n=1099)
♦ Not meeting inclusion criteria(n=1046)
♦ Declined to participate (n=53)
♦ Other reasons (n=0)

Randomised (n=160)

Allocation
Allocated to control (n=80)
♦ Received allocated treatment (n=80)
♦ Did not receive allocated treatment (give
reasons) (n=0)

Allocated to intervention (n=80)
♦ Received allocated intervention (n=80)
♦ Did not receive allocated intervention (give
reasons) (n=0)

Follow-Up
Lost to follow-up (give reasons) (n=17)
Phone number disconnected (n=2)
Participant did not answer (n=15)
Discontinued treatment (give reasons) (n=0)

Lost to follow-up (give reasons) (n=21)
Phone number disconnected (n=3)
Participant did not answer (n=18)
Discontinued intervention (give reasons) (n=0)

Analysis
Analysed (n=63)
♦ Excluded from analysis (give reasons) (n=17)
17 participants lost to follow-up.

Analysed (n=59)
♦ Excluded from analysis (give reasons) (n=21)
21 participants lost to follow-up.
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Sample size and strategy:
In total, 1259 customers were screened for eligibility; 213 customers were eligible and 160 were
recruited. Eighty participants were recruited to the control group and 80 to the intervention group.

The intervention:
The ‘smoker’s face’ simulations were created using a digital photograph (6.0 megapixels) taken of the
intervention participants and uploaded to April® Face Aging Software (Version 2.5) on a laptop
computer.

Data collection:
The RCT was conducted between January 2010 and December 2010 and all follow-up surveys were
completed by June 2011. The final six-month follow-up showed a response rate of 78% for the
control group and 73% for the intervention group. The demographic and baseline smoking
behaviours of recruited participants are shown and compared between groups (intervention versus
control) in Table 2.
Table 2. Demographic and baseline smoking profile of study participants. The P-value is based on
the chi-square statistic (unless otherwise marked), and compares the treatment groups.
Variable
Male
Age: mean (SD)
Education:
Year 10 high school
Year 12 high school
TAFE/ technical qualif
Degree (univ/college)
Cigarettes per day/last 30 days
1
2-5
6-10
11-20
21+
Fagerström score: Mean (SD)
Fagerström dependency score:
0-2
3-4
5
6-7
8-10

Control group (N=80)
n (%)
35 (44%)
25.1 (4.1)

Treatment group (N=80)
n (%)
25 (31%)
24.2 (4.1))

15 (19%)
31 (39%)
17 (22%)
16 (20%)

17 (21%)
29 (36%)
22 (28%)
12 (15%)

11 (14%)
9 (11%)
21 (26%)
27 (34%)

19 (24%)
10 (13%)
14 (18%)
29 (36%)
8 (10%)

P-value
.10
a
.16
.71

.35

12 (15%)
2.96 (2.52)
39 (49%)
19 (24%)
8 (10%)
10 (12%)
4 (5%)

2.87 (2.48)

a

.82
.92

39 (49%)
18 (23%)
10 (13%)
10 (13%)
2 (3%)
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a

t-test
There appeared a trend towards more females, and lighter smokers (smoking up to five cigarettes per
day) in the intervention group however there were no statistically significant differences between
control and intervention groups on demographic or smoking dependence variables at baseline. No
participants were revealed with body dysmorphia. A number of questions on the survey were
designed to gather the respondents’ opinions of self-perceptions, and attitudes towards their smoking
behaviour. These questions were taken from an earlier survey [11], and showed that the groups were
generally well-matched. However, a greater proportion of the intervention group appeared to be
concerned about their physical appearance (83% versus 68%; P=.03, Chi-square test), and believed
that facial wrinkles were associated with smoking (99% versus 85%; P=.002, Chi-square test). There
was no difference in the proportion of participants in each group who had made at least one attempt
to quit smoking in the past (68% versus 71%, P=.73, Chi-square test).

Primary outcomes measured:
Table 3 shows the response rates to the follow-up surveys, and the change in smoking behaviour
over the study. There was a significant difference in the proportion of participants self-reporting to
have successfully quit smoking by the six-month survey. Assuming that participants who failed to
complete the final follow-up survey continued to smoke, only one out of 80 control participants (1.3%,
95% Confidence Intervals 0% to 6.7%) were confirmed non-smokers, compared to 11 out of 80
participants (13.8%, 95% Confidence Intervals 7.8% to 22.9%) of the intervention group. This
difference in confirmed quitting is highly statistically significant (P=.003, Chi-square test). The
intervention group contained a larger proportion of subjects responding to the question: “I care about
how people think I look”. A logistic regression model was used to investigate the association between
treatment group and self-reported quitting, after adjustment for this difference as well as the small
differences between groups in gender and nicotine dependence. The P-value associated with the
treatment group remained strongly significant after adjustment for these potentially confounding
variables (P =.003).
A similar model, using ‘confirmed quitting’ as the dependent variable, showed an adjusted P -value for
the treatment group of P =.03.
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Table 3. Pattern of survey completion, and change in smoking behaviour at six months.
The P-values are calculated using the Chi-square statistic unless otherwise specified.
Variable

Control group
(N=80)
n (%)

Treatment group
(N=80)
n (%)

Response to follow-up questionnaires
All surveys completed
56 (70%)
48 (60%)
Incomplete: Last survey completed:
6 month
6 (8%)
10 (13%)
3 month
8 (10%)
14 (18%)
1 month
3 (4%)
4 (5%)
No follow-up
7 (9%)
4 (5%)
Quit smoking at 6 months:
Self report (questionnaire)
5 (6.3%)
22 (27.5%)
Confirmed (CO)
1 (1.3%)
11 (13.8%)
Change in Fagerstrom smoking
dependence score at 6 months
Reduced dependence
11 (14%)
41 (51%)
No change
68 (85%)
39 (49%)
Increased dependence
1 (1%)
0
Change in mean Fagerstrom score
from baseline to:
1 month
-0.14
-0.83
3 months
-0.38
-1.34
6 months
-0.26
-1.88
^ Fisher’s Exact test
§ Obtained from a repeated measures analysis including all available surveys

P-value

.38

<.001
.003
<.001^

<.001§

Table 3 also shows changes in the Fagerström smoking dependence score. Firstly, the six-month
score was grouped into the five broad dependence level categories, and compared with baseline
data. There was a significant difference in change in smoking dependence between groups (P<.001,
Chi-square test), with 14% of the control group moving to a lower category compared to 51% of the
intervention group doing so.

A random effects regression model was used to model the mean change in Fagerström score from
baseline, using data from all follow-up surveys The control group did not experience a significant
drop in Fagerström score over the study (P =.36), while the participants in the intervention group
dropped by an average of approximately 1.9 points (P =.002). The change in mean scores over the
whole study was very significantly different between treatment and control groups (P <.001, Table 3).
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Although there were no differences between participants at baseline, the regression models were
extended to adjust for the gender and age of the participant, and the number of cigarettes smoked at
baseline. The models were fitted to the control and intervention group separately, as it was clear that
changes in score appeared only in the intervention group. For the control group, there were no
associations between change in score and age (P =.14), sex (P =.72) or baseline consumption
(P =.49). However, for the intervention group, age (P <.001) and baseline consumption (P <.001)
were significantly associated with the change in score while gender (P =0.34) was not associated.
Older participants were less likely to reduce their score than younger participants, suggesting that the
intervention may have a greater effect on the younger participants. Participants who smoked more
than 10 cigarettes per day showed a significant drop in score of at least one point on the Fagerström
scale (P <.001), independently of age. Participants smoking 6–10 cigarettes per day showed a trend
towards a lowering in score (P =.07), while light smokers (0–5 cigarettes per day) showed no change
in score.

Secondary outcomes measured:
Total costs of implementing the intervention from a health sector perspective were AUD 463 or the
equivalent of AUD 5.79 per participant (Table 4).

Table 4. Economic analysis of photo-ageing service
Item

Base case

Scenario sensitivity
analysis
‘Best-case’ ‘Worst-case’
5.07
8.93
406
714

Mean cost per participant of service (AUD)
Total cost of service – 80 participants (AUD)

5.79
463

Incremental cost-effectiveness ratio (ICER)
- cost per additional quitter (AUD)
- cost per additional lifetime quitter (AUD)

46
74

41
64

71
113

2,144
1,778

2,660
2,346

1,867
1,316

20.25 (15.32)
20.00
[10.00; 20.00]

-

-

Cost offset from reduction in health care costs (AUD)
Net total cost savings (AUD)
Mean willingness to pay for service (AUD) (SD)
Median willingness to pay for service (AUD) [IQR]

With an additional 10 quitters confirmed in the intervention group compared with the control group (11
versus one respectively), the incremental cost-effectiveness ratio (ICER) was AUD 46 per additional
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quitter, or the equivalent of AUD 74 per additional lifetime quitter. Cost offsets of AUD 2,144 from a
reduction in the health care costs of quitters resulted in the intervention potentially generating net total
cost savings of AUD 1,778. In the ‘best-case’ scenario the ICER was AUD 41 per additional quitter
and net total cost savings were AUD 2,346. Corresponding figures for the ‘worst-case’ scenario were
AUD 71 per additional quitter and AUD 1,316 respectively.

The mean cost which the participants indicated that they were willing to pay for the digital ageing
service was AUD 20.25, which exceeded the mean cost per participant for delivering the service
(AUD 5.79). The median cost they were willing to pay was AUD 20 which was similar to the mean
value. Over 80% of participants said they would be more likely both to use the pharmacy to purchase
future smoking cessation therapies and to use it more generally for other purchases. Over 80% of
participants also thought their friends would be willing to pay for the service and all but two
participants said they would recommend the photo-ageing intervention to one or more friends who
were smokers.

DISCUSSION
Summary of findings:
The impact of the photo-ageing innovation on confirmed quit attempts by the young people recruited
to this study was highly significant (P=.003, Chi-square test). The data further demonstrate that
overall the photo-ageing intervention had a larger influence on younger participants. Also, the
participants who did not make a quit attempt but who smoked more than 10 cigarettes per day, were
likely to become less dependent on nicotine.

Strengths and weaknesses of the study:
The pharmacies selected to take part in the study were chosen to cover a range of socioeconomic
areas and the equal number of study participants selected for each treatment group at each
pharmacy aimed to diminish any potential biases. However due to the nature of the intervention the
participants and researcher could not be blinded to the study group. Allocation to groups was not
performed as eligible participants were recruited, but according to the treatment being used at the
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pharmacy during that week. In this setting there was a substantial risk of contamination between
treatment and control group if participants had been randomised at the point of recruitment rather
than by week of attendance at the pharmacy.

The baseline comparisons showed that the two groups were very similar on smoking dependence
scores, and the six-month follow-up response rate was high (over 70% for both groups). Follow-up to
12 months may have been preferable but impractical in this case. However follow-up at six months
was augmented by biochemical verification of tobacco use and cessation [26]. If participants stated
they had made a quit attempt at the six-month conclusion of the study, they were invited to undertake
a CO monitor test to validate their non-smoking status. It was disappointing that so few participants in
the control group agreed to CO verification. There are two possible reasons for this, it is possible that
they continued to smoke or they were not as engaged in the project as the intervention group and
were less amenable to follow-up. Nevertheless the self-reported smoking status data are interesting
and although quite likely to be prone to socially desirable responses, the effect size is still substantial
and on a par with other intervention trials.

We also noted a trend towards more females and light smokers in the intervention group, although on
analysis this appeared not to diminish the very significant statistical association between treatment
group and quitting smoking.

Strengths and weaknesses in relation to other studies:
While many individualised smoking cessation interventions have been implemented in the last few
decades few have had as marked an impact as reported here. With the advent of digital technology,
quit messages can now be delivered by mobile telephone, email, text messaging and online social
networks [27].

To date, there have been few studies reporting on a personalised photo-ageing intervention [12-14],
those published have only recruited females, and only one of these studies was an RCT which
recruited a small number of female smokers who had been referred to a smoking cessation service
[14].
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Implications for clinicians and policy-makers:
The economic analysis demonstrates that this personalised smoking cessation intervention is cheap
and cost-effective and it could be readily adopted in community pharmacies. It targets young smokers
who are at significant risk of adverse effects of smoking if they continue lifelong smoking.

With an ICER of AUD 74 per additional lifetime quitter, the intervention is cost-effective compared with
other individualised smoking cessation programs. For example, a systematic review of economic
evaluations of a range of smoking cessation interventions found ICERs of between USD 260 to USD
3263 per lifetime quitter (US 2002) for counselling or self-help programs versus usual care [28].
These ICERs are of a similar order of magnitude as reported elsewhere for brief advice from a
general practitioner to quit smoking and smoking cessation counselling of GBP 196 and GBP 653 per
lifetime quitter respectively (GBPs 1999) [29]. Although these other studies calculated ICERs based
on a societal perspective, additional non-health care costs of the photo-ageing interventions such as
patient time input are minimal.

Unanswered questions and future research:
A review commissioned by the Australian Commonwealth Department of Health and Ageing
concluded that interventions delivered by health care providers significantly increased the number and
success of quit attempts made in Australia each year [30].
Health care providers such as pharmacists are accessible and highly trained [31]. They have an
established a role in delivering smoking cessation pharmacotherapies and other forms of cessation
assistance [32, 33]. Could this intervention also be delivered by other health care providers in
community settings such as family medicine or allied health clinics?

A significant development for the use of mass media in delivering anti-smoking messages is the
advent of digital technology. Technologies such as the Internet, social networking sites and smart
phones, have the potential to reach large populations of younger people [2, 28, 34]. Could this
internet technology be delivered to the public without professional facilitation and would it have the
same effect?
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Further experimental research deploying photo-ageing technology is needed.
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